Photodynamic Therapy Market Size, Share, Growth, and Regional Forecast, 2025 - 2032

The global photodynamic therapy market is expected to reach US$3.7 billion in 2025 and US$6.0 billion at a CAGR of 7.2% during the forecast period from 2025 to 2032.

The global photodynamic therapy (PDT) market is expanding steadily, driven by rising cancer incidence, growing preference for minimally invasive treatments, and increasing availability of advanced photosensitizers and light-based devices. North America leads due to its established oncology infrastructure and reimbursement policies. At the same time, the Asia Pacific is the fastest-growing region, driven by rising healthcare investments and expanding adoption of cancer treatments.

• Leading Region: North America, holding nearly 39.0% market share in 2025, driven by established oncology infrastructure, high adoption of minimally invasive treatments, and strong presence of key photodynamic therapy device and drug manufacturers.
• Fastest-Growing Region: Asia Pacific, fueled by rising cancer prevalence, increasing healthcare expenditure, and rapid adoption of advanced light-based therapies in countries like China, Japan, and India.
• Investment Plans: Europe, focusing on clinical research collaborations, development of next-generation photosensitizers, and regulatory harmonization to enhance treatment efficacy and patient safety.
• Dominant Product: Photosensitizer drugs, capturing nearly 63.4% market share, due to their essential role in PDT procedures and growing use in oncology and dermatology applications.
• Growth Indicator: Increasing cancer incidence, expanding dermatological applications, advancements in light-delivery systems, and rising demand for non-invasive therapies are driving the Photodynamic Therapy Market.
• Market Opportunity: Growing R&D in targeted photosensitizers, integration of PDT with immunotherapy, and expansion into emerging markets present significant growth opportunities for manufacturers and healthcare providers.

Driver - Innovation in Drug-Device Combinations

Innovation in drug-device combinations is increasingly driving the Photodynamic Therapy (PDT) market, as the approach pairs a photosensitizing drug with a light-delivery device to enhance selectivity and outcomes. The first approved PDT regimen – the drug-device combo of Porfimer sodium (Photofrin) plus laser light – was approved by the U.S. Food and Drug Administration (FDA) in 1995 for esophageal cancer, and subsequently for other indications.

Recent clinical and bench research show that integrating targeted delivery systems (e.g., nanosyringes delivering photosensitizers and oxygen) with real-time light dosimetry markedly improves efficacy in solid tumors. For example, a U.S. SBIR-funded project (≈ US$1.97 million) is developing hardware/software that integrates real-time dosimetry for interstitial PDT of deep tumors. Moreover, a meta-analysis in ophthalmology found that combining PDT with anti-VEGF drugs achieved polyp regression rates up to ~ 77.8 %, versus ~ 26.7 % with monotherapy. Together, the data show that drug-device combinations in PDT not only enhance therapeutic precision and outcomes but also broaden the scope of treatable indications, fueling market expansion.

Restraints - Lack of Standardization of Treatment Protocols

Lack of standardized PDT protocols remains a key restraint: approved photosensitizers and devices have widely varying dosing, incubation times, light wavelengths and dosimetry, which undermines reproducibility and reimbursement. For example, FDA approvals for PDT agents span decades (Photofrin/porfimer sodium approved 1995; Levulan/5-ALA approved 1999), yet clinical reports show inconsistent parameter reporting across trials. ClinicalTrials.gov lists dozens of PDT studies, reflecting active investigation but heterogeneous designs that impede meta-analysis. Peer-reviewed reviews and systematic summaries repeatedly call out this heterogeneity and the need for consensus on dose, light source and endpoint measurement to allow pooled evidence and guideline development. State/regional reviews likewise note that variable protocols prevent demonstration of superiority among modalities. That combination, legacy approvals, many small heterogeneous trials, and inconsistent dosimetry, slows guideline uptake, limits payer coverage, and restrains wider clinical adoption of PDT.

Opportunity - Development of Novel Photosensitizers

Development of novel photosensitizers offers a transformative opportunity in the Photodynamic Therapy (PDT) market by addressing key limitations of existing agents, such as shallow light penetration and prolonged photosensitivity. Modern research funded by the U.S. National Institutes of Health (NIH) and the European Commission focuses on next-generation chlorins, bacteriochlorins, and nanoparticle-based photosensitizers that can be activated by near-infrared (NIR) light, enabling deeper tissue penetration. For instance, NIH data show more than 70 ongoing PDT-related grants targeting nanocarrier or oxygen-enhanced photosensitizers, reflecting strong translational interest.

Additionally, clinical trials registered demonstrate increasing exploration of photosensitizers linked to monoclonal antibodies and immune-stimulatory agents, aiming to combine PDT with immunotherapy. These innovations promise improved tumor selectivity, faster clearance, and reduced side effects, expanding PDT’s utility beyond dermatology and oncology into antimicrobial, ophthalmic, and cardiovascular applications, thus creating substantial commercial and clinical growth opportunities.

By Product Type, Photosensitizer Drugs dominate the Photodynamic Therapy Market

Photosensitizer Drugs dominate the market with a 63.4% share in 2025 because they are the core therapeutic component responsible for light-induced cytotoxic effects on target tissues. Their dominance is supported by the wide clinical adoption of U.S. FDA-approved agents such as porfimer sodium (Photofrin), aminolevulinic acid (Levulan Kerastick), and methyl aminolevulinate (Metvixia) for treating cancers and actinic keratosis. According to the U.S. FDA’s Center for Drug Evaluation and Research, photosensitizers are involved in over 80% of active PDT-related Investigational New Drug (IND) applications. Moreover, ClinicalTrials.gov lists more than 150 ongoing studies evaluating novel photosensitizers for oncology and dermatology, underscoring their clinical importance and regulatory momentum, making this segment the cornerstone of PDT’s growth and therapeutic expansion.

By Indication, Cancer is Gaining Traction due to rising cancer cases and proven tumor-targeting therapeutic efficacy.

Cancer dominates the Photodynamic Therapy (PDT) market because PDT has shown strong efficacy in targeting malignant and pre-malignant tumors with minimal damage to surrounding tissues. According to the World Health Organization (WHO), cancer remains one of the leading causes of death globally, responsible for 10 million deaths in 2022, creating urgent demand for safer, localized treatments. PDT is widely approved for cancers such as non-small cell lung cancer, esophageal cancer, and skin cancers by the U.S. FDA and European Medicines Agency (EMA). Furthermore, ClinicalTrials.gov lists over 200 ongoing PDT cancer trials, highlighting active clinical development. This strong clinical backing and growing oncology burden drive the cancer segment’s dominance within the global PDT market.

North America Photodynamic Therapy Market Trends

The North America region dominates the global market with a 39.0% share in 2025, due to advanced healthcare infrastructure, high cancer prevalence, and strong adoption of minimally invasive treatments. According to the U.S. National Cancer Institute (NCI), over 2 million new cancer cases are projected in the U.S. by 2025, driving demand for targeted therapies such as PDT. The FDA’s approval of next-generation photosensitizers, such as porfimer sodium and aminolevulinic acid, has accelerated their clinical use across oncology and dermatology. Additionally, the National Institutes of Health (NIH) supports ongoing PDT research, enhancing treatment precision and safety. Combined with high healthcare spending, nearly 17% of GDP in the U.S. (OECD, 2024), these factors solidify North America’s dominance in the global PDT market.

Europe Photodynamic Therapy Market Trends

Europe is a significant region, with a 25.5% share in 2025, driven by strong regulatory support, advanced clinical research, and widespread adoption in oncology and dermatology. The European Medicines Agency (EMA) has approved several photosensitizer drugs, including temoporfin and aminolevulinic acid, for treating skin cancers and precancerous lesions.

According to Cancer Research UK, Europe records over 3.7 million new cancer cases annually, creating high demand for minimally invasive therapies like PDT. The region also benefits from robust healthcare funding, with countries such as Germany, France, and the UK investing heavily in photomedicine and hospital infrastructure. Additionally, the EU Horizon research programs continue to fund PDT innovation, reinforcing Europe’s pivotal role in advancing therapeutic technologies.

Asia Pacific Photodynamic Therapy Market Trends

Asia Pacific is the fastest-growing region in the photodynamic therapy market, driven by rising cancer burden, expanding healthcare infrastructure, and increasing government investments in advanced oncology care. According to the World Health Organization (WHO), Asia accounts for nearly 50% of global cancer cases, with countries like China, Japan, and India showing rapid growth in non-invasive cancer treatment adoption. The Chinese National Medical Products Administration (NMPA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) have accelerated approvals for photosensitizer drugs and PDT devices, supporting faster market entry. Growing awareness of skin and oral cancer prevention, along with expanding clinical research collaborations, positions the Asia Pacific as the leading growth hub for photodynamic therapy over the coming years.

The global photodynamic therapy market is expanding as manufacturers advance photosensitizer formulations, device precision, and light delivery systems. Leading players focus on improving treatment safety and selectivity, while emerging firms explore novel photosensitizers and drug-device combinations. Strategic collaborations, clinical research investments, and regulatory approvals are driving PDT adoption in oncology, dermatology, and ophthalmology.

Key Industry Developments:

• In September 2025, Biofrontera Inc. announced that the last patient had completed participation in its Phase 3 clinical study evaluating Ameluz® (aminolevulinic acid HCl) topical gel, 10%, used in Photodynamic Therapy (PDT) for treating actinic keratoses (AK) on the extremities, neck, and trunk.
• In September 2025, Soligenix announced that it had expanded its European Medical Advisory Board to strengthen clinical guidance and research strategies for cutaneous T-cell lymphoma (CTCL). The expanded board included leading dermatology and oncology experts from across Europe, aiming to support ongoing development of Soligenix’s Photodynamic Therapy (PDT) and other targeted treatments for rare skin lymphomas.
• In June 2025, Biofrontera Inc. announced that it had completed a major restructuring of its relationship with Biofrontera AG, supported by an $11 million investment. The restructuring aimed to streamline operations, strengthen financial independence, and enhance collaboration between the two companies
• In May 2025, Sun Pharmaceutical Industries Ltd. announced that it had received U.S. FDA approval for its next-generation BLU-U® Blue Light Photodynamic Therapy Illuminator for the treatment of actinic keratosis. The upgraded device featured enhanced illumination technology to improve treatment precision and patient comfort.
• In July 2024, Biofrontera AG successfully hosted a CME-certified training event titled “Photodynamic Therapy (PDT) at the Cutting Edge” in Berlin. The program brought together dermatology professionals and researchers to discuss the latest advancements in PDT techniques, photosensitizer innovations, and clinical applications. The session emphasized improving treatment outcomes and expanding physician expertise in light-based cancer and skin therapies.